Market-Moving News for July 18th
$AGEN
$BYND
$NKGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Packaged Foods
Consumer Staples
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 7/19/2024 | $35.00 → $8.00 | Outperform → Neutral | Robert W. Baird | |
| 7/18/2024 | Outperform → Mkt Perform | William Blair | ||
| 7/18/2024 | $9.00 | Buy → Neutral | H.C. Wainwright | |
| 2/29/2024 | Sell → Hold | Argus | ||
| 11/13/2023 | $5.00 | Equal Weight → Underweight | Consumer Edge Research | |
| 10/12/2023 | $12.00 → $5.00 | Neutral → Underperform | Mizuho | |
| 9/13/2023 | $10.00 | Underperform | TD Cowen | |
| 6/6/2023 | $8.00 | Outperform | Robert W. Baird |
Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran
SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Gottardis is the owner of, and has served as a consultant at, Gottardis Biotech LLC, a biopharmaceuticals and research and development consultancy firm, since February 2023. Dr. Gottardi
Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - AGENUS INC (0001098972) (Subject)
SC 13G/A - BEYOND MEAT, INC. (0001655210) (Subject)
NT 10-Q - NKGen Biotech, Inc. (0001845459) (Filer)
8-K - NKGen Biotech, Inc. (0001845459) (Filer)
10-Q - AGENUS INC (0001098972) (Filer)
The delicious, flavor-forward links are made from wholesome plant-based ingredients including yellow pea, brown rice, faba bean and red lentil proteins and available in three irresistible flavors: Cajun, Pesto and Pineapple Jalapeño With 12g of clean protein per link and just 1g of saturated fat, Beyond Sun Sausage is certified as a heart-healthy food by the American Heart Association's Heart-Check program and the American Diabetes Association's Better Choices for Life programEL SEGUNDO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Today, Beyond Meat (NASDAQ:BYND), a leader in plant-based meat, debuted a new product line with the introduction of Beyond Sun Sausage™. Filled with wholesome ingred
Beyond Meat, Inc. (NASDAQ:BYND) shares are trading lower on Monday on continued weakness after it was reported late last week that the company’s liquidity position had deteriorated caused the stock to drop. What To Know: The report also suggested that the company reached out to a group of bondholders to start discussions about restructuring its balance sheet. Last Thursday, the company’s stock was trading around $6.20. As of Monday morning, the stock is trading at $5.80. The current trading price is at the bottom of its 52 week range of $5.58 to $17.96 and below its 50 day moving average of $7.08. Beyond Meat is anticipated to release quarterly financial earnings on August 5. Analys
Shares of Tellurian Inc. (NASDAQ:TELL) rose sharply in today's pre-market trading after Woodside Energy announced plans to acquire the company for $900 million in all-cash deal. The implied enterprise value is around $1,200 million. Tellurian shares jumped 65% to $0.9422 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Netcapital Inc. (NASDAQ:NCPL) rose 43.8% to $0.1495 in pre-market trading after jumping more than 12% on Friday. Netcapital, last week, announced the launch of the beta version of its secondary trading platform. Serve Robotics Inc. (NASDAQ:SERV) gained 36.8% to $10.33 in pre-market trading. Serve Robotics shares jumped
Following a successful initial launch, Beyond Meat's healthy, flavor-forward plant-based links are debuting at Whole Foods Market stores coast-to-coast Beyond Sun Sausage is filled with wholesome ingredients from legumes and vegetables and offers 12g of clean protein per link with 1g of saturated fat, meeting the rigorous nutritional guidelines of the American Heart Association's Heart-Check program and the American Diabetes Association's Better Choices for Life program EL SEGUNDO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Beyond Meat, Inc. (NASDAQ:BYND), a leader in plant-based meat, today announced that its newest product innovation, Beyond Sun Sausage™, is rolling out at Whole Foods M
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational immunotherapy candidates, botensilimab and AGEN1721, at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting in Houston, Texas. The data, showcasing potential breakthroughs in treating immune-resistant tumors, will be presented by Dhan Chand, Ph.D., Vice President of Research at Agenus. The first two presentations will spotlight botensilimab, an innovative, investigational, Fc-enhanced ant
Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously
William Blair downgraded Agenus from Outperform to Mkt Perform
H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413. About A
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)
4 - AGENUS INC (0001098972) (Issuer)